Five Things You Should Think About on Your Healthcare Marketing Journey
Healthcare marketing isn’t just about launching a campaign or checking boxes. It’s about building clarity, trust, and connection in an industry where accuracy and intention matter deeply. No matter where you are in your journey, grounding yourself in a few core principles can make your work more focused and more effective. Here are five things […]
The Importance of Marketing in the Healthcare Industry: Understanding the “Why”
Written by Georgette “G” Pascale – Founder of G. and Friend of LaunchLab Partners Everyone talks about the “how do you do it” in marketing, yet when you have a busy day job and are in either pre, peri or post launch, sometimes it can seem overwhelming or even unnecessary to understand why we implement […]
TearOptix Secures Strategic Funding to Transform Presbyopia Treatment and Announces Creation of Scientific Advisory Board
ATHERTON, Calif.–(BUSINESS WIRE)–TearOptix, Inc., a pioneering contact lens company developing advanced solutions for patients with presbyopia, today announced the completion of a strategic corporate financing round led by investors with deep expertise in ophthalmology. Presbyopia is the gradual loss of the eye’s ability to focus on nearby objects, affecting virtually everyone over the age of […]
DefEYE, Inc. Announces Investment from ExSight Ventures
Investment Supports Commercialization of Innovative Decellularized Placental Tissue Technology for Ocular Surface Disease and Surgical Management NEW YORK–(BUSINESS WIRE)–ExSight Ventures, a leading venture capital firm focused on transformational eye care innovations, today announced its investment in DefEYE, Inc., a rapidly growing ocular company developing decellularized placental-based tissue solutions to transform and personalize therapeutic approaches in […]
Sydnexis Announces UK Approval of Ryjunea® by Partner Santen to Slow Progression of Childhood Myopia
DEL MAR, Calif.–(BUSINESS WIRE)–Sydnexis, Inc., a biopharmaceutical company focused on pediatric progressive myopia (PPM), today noted its partner Santen’s announcement that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ryjunea® (low-dose atropine 0.1 mg/ml), the first MHRA approved treatment in the UK to slow the progression of myopia in children aged 3-14 years […]
Sydnexis Announces Topline Pivotal Data from Phase 3 STAR Trial of SYD-101 for Patients with Pediatric Progressive Myopia Presented at AMCP Nexus 2025
Largest global clinical trial in pediatric myopia met primary efficacy endpoint of proportion of patients with confirmed progression of -0.75D and key secondary endpoint of annual progression rate Treatment effects evident by month 12 and sustained through month 36; greatest treatment benefit observed in younger children, in participants with a history of myopia progression, or when administered […]
Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care
FLORHAM PARK, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, announced today a strategic partnership with DefEYE, Inc. (“DefEYE”), a newly established ophthalmic product and technology company. Celularity has executed an exclusive license & pricing arrangement with DefEYE on the backend […]
Aurion Biotech Achieves All Primary, Secondary, and Exploratory Endpoints in AURN001 Phase 1/2 CLARA Trial at 12 Months
Data strongly supports advancing high dose AURN001 regenerative cell therapy for patients with corneal endothelial disease to pivotal Phase 3 trial in H1 2026 Seattle, WA; Cambridge, MA; Tokyo, Japan – 18 October – Aurion Biotech, a clinical-stage regenerative medicine company with a mission to restore vision to millions of patients, today announced positive 12-month results from […]
Aurion Biotech Achieves All Primary, Secondary, and Exploratory Endpoints in AURN001 Phase 1/2 CLARA Trial at 12 Months
Data strongly supports advancing high dose AURN001 regenerative cell therapy for patients with corneal endothelial disease to pivotal Phase 3 trial in H1 2026 Seattle, WA; Cambridge, MA; Tokyo, Japan – 18 October – Aurion Biotech, a clinical-stage regenerative medicine company with a mission to restore vision to millions of patients, today announced positive 12-month results from […]
DefEYE, Inc. and Lovell Government Services Announce Partnership to IncreaseAccess to the Biovance Product Portfolio for VA/DoD Health Affairs
PENSACOLA, Florida — October 9, 2025 – Lovell® Government Services (Lovell) and DefEYE,Inc. (DefEYE), an exclusive provider of BIOVANCE® decellularized basement membranes forocular use, announced today that they have partnered to serve federal healthcare systemsincluding the Veterans Health Administration, the Department of Defense Military HealthSystem, and the Indian Health Service. Lovell will serve as DefEYE’s […]
